Literature DB >> 30289313

CALCIUM CREATININE CLEARANCE RATIO IS NOT HELPFUL IN DIFFERENTIATING PRIMARY HYPERPARATHYROIDISM FROM FAMILIAL HERPERCALCEMIC HYPOCALCIURIA: A STUDY OF 1000 PATIENTS.

Edwina C Moore, Eren Berber, Judy Jin, Vikram Krishnamurthy, Joyce Shin, Allan Siperstein.   

Abstract

OBJECTIVE: With increasing recognition of more subtle presentations of primary hyperparathyroidism (pHPT), laboratory values are frequently seen in a range that would be expected for patients who have familial hypercalcemic hypocalciuria (FHH). Calcium creatinine clearance ratio (CCCR) has been advocated as a diagnostic tool to differentiate between these two disorders. However, it is limited by an indeterminate range (0.01-0.02). The aim of this study is to assess the relevance of CCCR in a modern series of patients with surgically managed pHPT.
METHODS: We performed a retrospective cohort study of 1000 patients who underwent parathyroid surgery for pHPT over eleven years. CCCR was evaluated by degree of biochemical derangement, single versus multiple gland disease and interfering medications.
RESULTS: Patient demographics and resected histopathology were typical for a current series of patients with pHPT. In retrospect, none of the patients were suspected to have FHH post operatively. CCCR was less than 0.01 for 19.0%, between 0.01-0.02 for 43.7% and greater than 0.02 in 37.3%. Distribution of CCCR for patients free from interfering medications and different histological subtypes were the same. One third of the cohort had mild calcium elevations, more typical for FHH. Of these, almost two thirds had a CCCR in a range suspect for FHH (<0.02).
CONCLUSION: To our knowledge this is the largest series to evaluate the validity of CCCR for patients with surgically confirmed pPHT. The utility of CCCR in screening for FHH is limited, as 63% of modern patients with confirmed pHPT have low values.

Entities:  

Year:  2018        PMID: 30289313     DOI: 10.4158/EP-2018-0350

Source DB:  PubMed          Journal:  Endocr Pract        ISSN: 1530-891X            Impact factor:   3.443


  7 in total

1.  Familial hypocalciuric hypercalcemia in an index male: grey zones of the differential diagnosis from primary hyperparathyroidism in a 13-year clinical follow up.

Authors:  K Zajíčková; M Dvořáková; J Moravcová; J Včelák; D Goltzman
Journal:  Physiol Res       Date:  2020-09-30       Impact factor: 1.881

Review 2.  Disorders of the Calcium Sensing Signaling Pathway: From Familial Hypocalciuric Hypercalcemia (FHH) to Life Threatening Conditions in Infancy.

Authors:  Jakob Höppner; Kathrin Sinningen; Adalbert Raimann; Barbara Obermayer-Pietsch; Corinna Grasemann
Journal:  J Clin Med       Date:  2022-05-05       Impact factor: 4.964

3.  Familial Hypocalciuric Hypercalcemia Type 1 and Autosomal-Dominant Hypocalcemia Type 1: Prevalence in a Large Healthcare Population.

Authors:  Ridge Dershem; Caroline M Gorvin; Raghu P R Metpally; Sarathbabu Krishnamurthy; Diane T Smelser; Fadil M Hannan; David J Carey; Rajesh V Thakker; Gerda E Breitwieser
Journal:  Am J Hum Genet       Date:  2020-05-07       Impact factor: 11.025

Review 4.  Persistent hypercalcemia with similar familial Hypocalciuric hypercalcemia features: a case report and literature review.

Authors:  Maryam Zahedi; Reyhane Hizomi Arani; Maryam Rafati; Atieh Amouzegar; Farzad Hadaegh
Journal:  BMC Endocr Disord       Date:  2021-11-04       Impact factor: 2.763

5.  A Novel Missense CASR Gene Sequence Variation Resulting in Familial Hypocalciuric Hypercalcemia.

Authors:  Panagiotis Bletsis; Rosemarie Metzger; J Alex Nelson; Justin Gasparini; Mahmoud Alsayed; Mira Milas
Journal:  AACE Clin Case Rep       Date:  2022-05-17

6.  Is routine 24-hour urine calcium measurement useful during the evaluation of primary hyperparathyroidism?

Authors:  Shimena R Li; Kelly L McCoy; Helena E Levitt; Meghan L Kelley; Sally E Carty; Linwah Yip
Journal:  Surgery       Date:  2021-07-27       Impact factor: 3.982

7.  Double jeopardy: a patient's tale of two concurrent hypercalcaemic syndromes.

Authors:  Aditi Sharma; Fatima Bahowairath; Chukwuma Uduku; Julia E Ostberg
Journal:  BMJ Case Rep       Date:  2020-08-25
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.